TY - JOUR
T1 - Receptors for peanut agglutinin (Arachus hypogea) in childhood acute lymphoblastic leukemia
T2 - Possible clinical significance
AU - Levin, S.
AU - Russell, E. C.
AU - Blanchard, D.
AU - McWilliams, N. B.
AU - Maurer, H. M.
AU - Mohanakumar, T.
PY - 1980
Y1 - 1980
N2 - The presence of lymphocyte receptors for peanut agglutinin in significant numbers (>15%) was identified on leukemic cells from T-cell acute lymphoblastic leukemia (T-ALL) (3/4), B-cell ALL (B-ALL) (2/4), null cell ALL (8/17), and on normal fetal thymic lymphocytes but not on normal human peripheral blood lymphocytes. Peanut agglutinin (PNA) binding was blocked specifically on leukemic lymphoblasts and thymic lymphocytes by the addition of galactose to the medium. When all immunologic subgroups of ALL are combined, preliminary data suggest that of the 13 ALL patients having greater than 15% PNA-positive lymphoblasts, 8 had relapsed, whereas none of the 12 ALL patients with less than 15% PNA-positive cells have recurrent disease at this time. It is likely that analysis of PNA receptors on ALL lymphoblasts may be useful adjunct to the existing clinical and immunologic prognostic indicators.
AB - The presence of lymphocyte receptors for peanut agglutinin in significant numbers (>15%) was identified on leukemic cells from T-cell acute lymphoblastic leukemia (T-ALL) (3/4), B-cell ALL (B-ALL) (2/4), null cell ALL (8/17), and on normal fetal thymic lymphocytes but not on normal human peripheral blood lymphocytes. Peanut agglutinin (PNA) binding was blocked specifically on leukemic lymphoblasts and thymic lymphocytes by the addition of galactose to the medium. When all immunologic subgroups of ALL are combined, preliminary data suggest that of the 13 ALL patients having greater than 15% PNA-positive lymphoblasts, 8 had relapsed, whereas none of the 12 ALL patients with less than 15% PNA-positive cells have recurrent disease at this time. It is likely that analysis of PNA receptors on ALL lymphoblasts may be useful adjunct to the existing clinical and immunologic prognostic indicators.
UR - http://www.scopus.com/inward/record.url?scp=0018919715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018919715&partnerID=8YFLogxK
U2 - 10.1182/blood.v55.1.37.37
DO - 10.1182/blood.v55.1.37.37
M3 - Article
C2 - 6965348
AN - SCOPUS:0018919715
VL - 55
SP - 37
EP - 39
JO - Blood
JF - Blood
SN - 0006-4971
IS - 1
ER -